The Interstate Council highlighted the results of the vaccine’s Phase III trial in the United States, which was 79% effective in preventing covid-19 and 100% effective in preventing serious diseases and hospitalizations, and also agreed to elaborate on its effectiveness. information. It is widespread in autonomous communities and promotes joint communication activities to increase confidence in vaccination.
This Regional Council The National Health System Administration has agreed to resume vaccination Oxford/AstraZeneca And expand to 65 years old The age limit of people receiving this vaccine in our country.
These decisions were made after learning of the conclusions of the European Medicines Agency’s Pharmacovigilance Risk Assessment Committee (PRAC) last Thursday (EMA), and the two-day meeting of the vaccine report and the Public Health Committee.
Besides Basic priority group Among the health and social health care personnel who have started to receive this vaccine (3-B, 3-C and 6) as previously unvaccinated, prison staff or other socially necessary personnel, such as teachers and special education personnel , Infant, Elementary and Intermediate or belong to security, emergency and armed forces agencies.
These working groups have considered Scientific evidence usable. Therefore, the annotations of the Phase III trial of AZD1222 in the United States are eye-catching. 79% efficiency Role in preventing symptomatic COVID-19 disease 100% prevention of serious illness and hospitalization. This also shows that it has 80% efficacy in people over 65 years old. It is beneficial to summarize the general safety and reactogenicity. To this end, we must add observational studies from the United Kingdom, which also provide positive data on effectiveness.
The regional councils, represented by all autonomous communities and cities, also agreed to develop a common message and promote joint advocacy activities to increase confidence in the vaccination process.